MSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model

[1]  G. Veronese,et al.  Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients , 2020, Journal of Molecular and Cellular Cardiology.

[2]  Z. Qian,et al.  Mesenchymal stem cells: current clinical progress in ARDS and COVID-19 , 2020, Stem Cell Research & Therapy.

[3]  S. Terai,et al.  Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases , 2020, Inflammation and regeneration.

[4]  John D Lambris,et al.  Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis , 2020, medRxiv.

[5]  Andrea Gianatti,et al.  Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study , 2020, The Lancet Infectious Diseases.

[6]  S. Metcalfe.  COVID-19 lockdown: de-risking exit by protecting the lung with leukaemia inhibitory factor (LIF) , 2020, Medicine in Drug Discovery.

[7]  V. Sengupta,et al.  Exosomes Derived From Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. , 2020, Stem cells and development.

[8]  C. Whyte,et al.  Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[9]  J. M. Crawford,et al.  Targeting potential drivers of COVID-19: Neutrophil extracellular traps , 2020, The Journal of experimental medicine.

[10]  Q. Ye,et al.  The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 , 2020, Journal of Infection.

[11]  Taojiao Wang,et al.  Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.

[12]  C. Cheung,et al.  Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) , 2020, Journal of General Internal Medicine.

[13]  Li-Sheng Wang,et al.  Growth Factor Gene-Modified Mesenchymal Stem Cells in Tissue Regeneration , 2020, Drug design, development and therapy.

[14]  D. Stakos,et al.  Traps N' Clots: NET-Mediated Thrombosis and Related Diseases , 2020, Thrombosis and Haemostasis.

[15]  D. Predescu,et al.  Mesenchymal stem cells-derived extracellular vesicles in acute respiratory distress syndrome: a review of current literature and potential future treatment options , 2019, Clinical and Translational Medicine.

[16]  Daniel Brodie,et al.  Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment , 2018, JAMA.

[17]  J. L. Rosa,et al.  Mesenchymal stem cells improves survival in LPS‐induced acute lung injury acting through inhibition of NETs formation , 2017, Journal of cellular physiology.

[18]  N. Abramov,et al.  miRNA profiling of NurOwn®: mesenchymal stem cells secreting neurotrophic factors , 2017, Stem Cell Research & Therapy.

[19]  K. Kuwano,et al.  Amphiregulin suppresses epithelial cell apoptosis in lipopolysaccharide-induced lung injury in mice. , 2017, Biochemical and biophysical research communications.

[20]  Min Zhang,et al.  Classically Activated Macrophages Protect against Lipopolysaccharide-induced Acute Lung Injury by Expressing Amphiregulin in Mice , 2016, Anesthesiology.

[21]  P. Rocco,et al.  Extracellular vesicles derived from mesenchymal stromal cells: a therapeutic option in respiratory diseases? , 2016, Stem Cell Research & Therapy.

[22]  E. Melamed,et al.  Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials. , 2016, JAMA neurology.

[23]  Shivakumar Keerthikumar,et al.  ExoCarta: A Web-Based Compendium of Exosomal Cargo. , 2016, Journal of molecular biology.

[24]  L. O’Driscoll,et al.  Biological properties of extracellular vesicles and their physiological functions , 2015, Journal of extracellular vesicles.

[25]  M. Matthay,et al.  Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis. , 2014, The Lancet. Respiratory medicine.

[26]  A. Dabo,et al.  Leukemia inhibitory factor protects the lung during respiratory syncytial viral infection , 2014, BMC Immunology.

[27]  Q. Shu,et al.  Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study , 2014, Respiratory Research.

[28]  B. Yu,et al.  Exosomes Derived from Mesenchymal Stem Cells , 2014, International journal of molecular sciences.

[29]  Matthew R. Jones,et al.  Leukemia Inhibitory Factor Signaling Is Required for Lung Protection during Pneumonia , 2012, The Journal of Immunology.

[30]  J. Laffey,et al.  Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat , 2011, Thorax.

[31]  Arthur S Slutsky,et al.  An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. , 2011, American journal of respiratory cell and molecular biology.

[32]  T. Martin,et al.  Animal models of acute lung injury , 2008, American journal of physiology. Lung cellular and molecular physiology.

[33]  S. Idell.  Coagulation, fibrinolysis, and fibrin deposition in acute lung injury , 2003, Critical care medicine.

[34]  J. Williams,et al.  Intratracheal injection of LPS and cytokines. V. LPS induces expression of LIF and LIF inhibits acute inflammation. , 1994, The American journal of physiology.

[35]  Qin Ning,et al.  Clinical and immunological features of severe and moderate coronavirus disease 2019 , 2020 .

[36]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.

[37]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..